High-dose intravenous glucocorticoid induces hyperamylasemia: a case series

Di Yang1 and Ming-hui Li2*

Abstract
Background: Glucocorticoids have many side effects, and high-dose intravenous application may cause rare adverse reactions such as hyperamylasemia. The aim of this study is to explore the clinical characteristics, treatment, and prognosis of hyperamylasemia induced by high-dose intravenous glucocorticoids.

Case presentation: Four Asian female patients, aged between 26 and 71 years, were diagnosed with hyperamylasemia after intravenous administration of high-dose glucocorticoid. Amylase levels were elevated to varying degrees in all patients, but the peaks were below three times the upper limit of normal, and imaging showed no significant pancreatic abnormalities. Two patients developed abdominal pain, which was resolved by inhibition of pancreatic secretion, while the other patients were asymptomatic. Two patients were discharged after a significant decrease in amylase levels, while the other two were discharged after improvement of the primary disease.

Conclusion: High-dose intravenous glucocorticoid can cause hyperamylasemia, which should be given enough attention by clinicians. Etiological differentiation of hyperamylasemia should be emphasized in clinical practice, especially when the diagnosis of acute pancreatitis is not clear.

Keywords: High-dose glucocorticoid, Intravenous application, Hyperamylasemia, Case report
patients, all Asian female, aged between 26 and 71 years old, with average age of 49.25 ± 18.38 were included in this study. To protect the privacy of the patients, we hid their real names, visiting department, hospitalization number, bed number, and other related information. Cases 1 and 2 were previously healthy, while cases 3 and 4 were accompanied by hypertension and renal insufficiency. There was no obvious abnormality in their family or psychosocial history, including related genetic information. Investigations on admission showed no history of pancreatic/salivary gland-related diseases or trauma, neoplasms, genital tract diseases, endoscopic retrograde cholangiopancreatography (ERCP) operation history, or abdominal surgery. In addition, patients were not diagnosed with hyperlipidemia, alcoholism, common drug factors (such as amino salicylic acid, thiopurine, and asparaginase), or megaamylasemia that can cause hyperamylasemia [6]. Basic information and clinical data of the four patients are presented in Table 1.

Clinical manifestations
Case 1 showed persistent upper abdominal pain and right abdominal tenderness, with no episodes of vomiting, diarrhea, or rebound pain following high-dose intravenous administration of mPSL. Case 2 had abdominal distension, persistent epigastric pain, with no other concomitant symptoms, either. Meanwhile, cases 3 and 4 did not show any significant symptoms. The positive physical examination results of the four cases were all related to the primary disease, and the abdominal physical examination showed no apparent abnormality.

Clinical findings
After high-dose intravenous administration of mPSL, serum amylase (AMY) levels increased in four patients, peaking at 193.1 to 340.4 U/L. In addition, increases in urine amylase and serum lipase were also observed. Abdominal enhanced CT scan performed after the occurrence of hyperamylasemia in case 1 showed sand-like stones in the gallbladder, with a normal shape of pancreas. In cases 2, 3, and 4, abdominal ultrasound performed prior to high-dose mPSL, indicated gallbladder sediment-like stones, rough gallbladder wall, and gallbladder stones, respectively. Notably, the CT scans in cases 2, 3, and 4 did not reveal any abnormalities of the pancreas. The AMY fluctuations of the four patients over time are shown in Fig. 1.

Diagnostic assessment and diagnosis
The above clinical manifestations, physical examinations, and clinical data were to be not very specific for diagnosis. Only cases 1 and 2 experienced epigastric pain, while enhancement CT in case 1 revealed gallstones. We were able to diagnose hyperamylasemia on the basis of the fact that the four patients had different elevations of AMY that exceeded the normal reference values of our hospital system. We speculate about the possibility of hyperamylasemia caused by high doses of intravenous GC through the adverse drug response evaluation described below. We considered whether this can be attributed to drug-induced pancreatitis, but imaging did not reveal any pancreatic abnormalities and therefore diagnostic criteria for pancreatitis were not met. The overall prognosis of the four patients is good.

| Case | Age/sex | Primary disease | Main symptoms | mPSL dose | AMY peak (U/L) | New symptoms | Other therapeutic drugs | Outcome |
|------|---------|-----------------|---------------|-----------|---------------|--------------|------------------------|---------|
| 1    | 49/F    | ADEM            | Fever, headache, jet vomiting | 500 mg/day for 7 days + 250 mg/day for 5 days + 120 mg/day for 5 days | 336.9 | Abdominal pain | Ceftriaxone sodium, acyclovir | Better |
| 2    | 26/F    | ADEM            | Fever, headache, dysuria | 80 mg q8h 2 days + 120 mg/day for 2 days + 200 mg/day for 2 days + 120 mg/day for 2 days | 340.4 | Abdominal distension, abdominal pain | Ceftriaxone sodium, acyclovir, piperacillin tazobactam | Better |
| 3    | 51/F    | SLE             | Tooth loss, abdominal pain, dry mouth, knee joint pain | 500 mg/day for 3 days | 193.1 | None | Cefotiam, cyclophosphamide | Discharged |
| 4    | 71/F    | Uremia, nephrotic syndrome | Gross hematuria, edema | 250 mg/day for 3 days + 250 mg/day | 257.9 | None | Piperacillin tazobactam, cyclophosphamide | Discharged |

ADEM Acute disseminated cerebrospinal meningitis, SLE systemic lupus erythematosus, F female
Interventions and outcomes
Case 1 and 2 underwent fasting. Then, they were given omeprazole to inhibit gastric acid, phloroglucinol as anti spasmodic, somatostatin to inhibit pancreatic enzyme secretion, and anti-infection and nutritional support treatment. Two patients were discharged after a significant decrease in AMY levels, and case 3 and 4 were discharged after improvement of the primary disease. At outpatient review, they indicated that mPLS was effective for the primary disease and that, despite the unexpected increase in AMY, subsequent active interventions led to normalization of AMY. Unfortunately, they have not been followed since then.

Discussion
Hyperamylasemia can be divided into four types: pancreatic hyperamylasemia, salivary gland hyperamylasemia, megaamylasemia, and mixed hyperamylasemia [7], being mainly due to pathological changes in the organs that secrete AMY and impaired metabolic clearance. Common causes such as acute pancreatitis, pancreatic or salivary gland trauma, ERCP, etc., lead to gland storage AMY secretion to the blood, resulting in hyperamylasemia. AMY is cleared through the kidney and reticuloendothelial system in the human body, and hyperstarchemia occurs in renal insufficiency and liver disease (hepatitis or cirrhosis) [5]. Studies have shown that AMY is increased in patients with chronic renal insufficiency when eGFR < 60 ml/min/1.73 m², and AMY increased level was negatively correlated with eGFR [8]. Cases 1 and 2 had normal renal function throughout the disease, while cases 3 and 4 had renal insufficiency, especially case 4, which could have been diagnosed as uremia, relying on hemodialysis for a long period of time to maintain renal function. On outpatient follow-up, we observed a normalization of amylase in the latter two, but there has been no significant recovery of renal function. Therefore, the possibility of increased amylase due to renal insufficiency was temporarily ruled out. The renal function results of the four cases are presented in Table 2.

Moreover, previous studies have reported that systemic lupus erythematosus is associated with elevated AMY, which can be attributed to the production of autoantibodies, immune process activation, and vasculitis-induced lupus pancreatitis [9]. Case 3, in which amylase was above normal on admission, was considered to be related to SLE. The amylase then decreased to normal with low doses of mPSL and cyclophosphamide. SLE was effectively treated with high-dose mPSL from day 8, after which amylase increased again, which was considered to be related to the high-dose mPSL. Interestingly, when case 3 was admitted for the second time, 60 mg of mPSL was administered for 13 consecutive days and a slight increase in amylase was noted.

Gallstone is the common cause of acute pancreatitis. In these four cases, we could almost observe gallbladder sediment-like stones, but before the application of

| Day | AMY (U/L) | CREA (umol/L) | UA (umol/L) | eGFR (mL/min/1.73 m²) |
|-----|-----------|---------------|-------------|-----------------------|
| Case 1 | 2 | 61.9 | 45.5 | 142.1 | 113 |
| 8 | 78.4 | 40.2 | 164 | 117.7 |
| 18 | 233.6 | 39 | 120 | 118.9 |
| 27 | 167.6 | 36.2 | 142.7 | 121.8 |
| Case 2 | 2 | 79.9 | 61.3 | 153 | 120.4 |
| 5 | 68.7 | 44.8 | 125.7 | 133.5 |
| 9 | 211.2 | 46.1 | 107.9 | 132.2 |
| 32 | 109.9 | 39.7 | 258.6 | 138.9 |
| Case 3 | 1 | 150.8 | 98.1 | 466.4 | 57.8 |
| 4 | 162.6 | 85.9 | 456.5 | 67.9 |
| 9 | 112.5 | 129.5 | 571 | 41.3 |
| 14 | 163 | 105.4 | 474.1 | 53 |
| 18 | 193.1 | 105.2 | 372.8 | 53.1 |
| Case 4 | 1 | 60.1 | 466.3 | 297.2 | 7.6 |
| 8 | 58.7 | 260.2 | 206.1 | 15.4 |
| 13 | 186 | 343.6 | 272 | 11 |
| 21 | 196.4 | 385.6 | 319.6 | 9.8 |
| 34 | 257.9 | 345.4 | 404.1 | 11 |

*CREA creatinine, UA uric acid, eGFR estimated glomerular filtration rate
high-dose glucocorticoid, amylase was normal, and there were no relevant imaging manifestations of acute pancreatitis, so we can reject the influence of gallbladder stones.

In this study, the relationship between mPSL and hyperamylasemia was evaluated by the Naranjo scoring method [10], as shown in Table 3, and the following is a detailed description of the contents of the rating scale. (1) According to literature, Logsdon et al. reported that GC induced synthesis of AMY by AR42J pancreatic acinar cells in 1985 [11], indicating that GC could cause an increase of amylase. (2) In addition, except for case 3, the other cases had normal AMY levels at admission, and hyperamylasemia occurred only after high dose of mPSL. (3) In cases 1 and 2, AMY secretion was inhibited by somatostatin, and hyperamylasemia was relieved. (4) The fluctuation of amylase can be used as objective evidence, and other possible causes of hyperamylasemia are excluded in the discussion above, indicating that effective diagnosis of hyperamylasemia was performed.

However, our research also has some limitations. For example, there was no mention of similar adverse drug reactions in patients’ previous medical history nor high dose of GC rechallenge. In this study, we did not carry out placebo-controlled trials or monitor blood concentrations after addition and subtraction doses to compare the severity of hyperamylasemia. Due to the failure of follow-up, we only know that the AMY of the four patients returned to normal after the first outpatient review, so it is impossible to predict whether hyperamylasemia will recur.

In summary, the total score for the above evaluation criteria was 7 points, indicating that the causal relationship of hyperamylasemia caused by high-dose mPSL is “very likely.”

Previous studies have reported that GCs can lead to acute pancreatitis [12–14]. China’s latest guidelines [15] suggest that the diagnosis of acute pancreatitis should meet at least two of the following three criteria: (1) acute, sudden, persistent, severe upper abdominal pain, which may radiate to the back; (2) serum amylase and/or lipase activities at least three times higher than the upper limit of normal levels; (3) enhanced CT/MRI showing typical AP imaging changes (pancreatic edema or peripancreatic effusion). These four cases did not meet the diagnostic criteria for pancreatitis, so the diagnosis was a simple increase in AMY caused by drugs, which might be a direct toxicity of mPSL.

**Conclusion**

Elevated amylase levels may be a result of pancreatitis or a reflection of nonpancreatic disease. Simple hyperamylasemia is clinically insignificant and does not require treatment. However, etiological differentiation of hyperamylasemia should be emphasized in clinical practice, especially when the diagnosis of acute pancreatitis is not clear. The hyperamylasemia in this study was most likely caused by acute pancreatitis, as the diagnosis has not yet been reached. It is recommended to increase tests of serum lipase, giant amylase, and pancreatic amylase isoenzyme as well as imaging examinations of pancreas when necessary, and to follow up outpatients with high amylase.

**Acknowledgements**

The authors would like to thank the reviewers for their helpful remarks and the associate editor for their useful feedback that improved this paper. We also appreciate the patients provided informed consent and our Infection staff for helping to collect clinical data.

**Author contributions**

DY completed data analysis and was in charge of paper writing; M-hL guided the design and paper revision. Both authors read and agreed the final text.

**Funding**

This work was supported by the Zhejiang Province Public Welfare Technology Application Research Project under grant [numbers 2021KY1138].

**Availability of data and materials**

All data generated or used during the study appear in the submitted article.

---

**Table 3** Naranjo scale questionnaire

| Naranjo questions                                                                 | Yes | No | Do not know |
|----------------------------------------------------------------------------------|-----|----|-------------|
| a Are there previous conclusive reports on this reaction?                         | 1   | 0  | 0           |
| b Did the adverse event occur after the suspected drug was administered?         | 2   | −1 | 0           |
| c Did the adverse reaction improve when the drug was discontinued or a specific antagonist was administered? | 1   | 0  | 0           |
| d Did the adverse reaction reappear when the drug was readministered?            | 2   | −1 | 0           |
| e Are there alternative causes (other than the drug) that could have on their own cause the reaction? | −1  | 2  | 0           |
| f Did the reaction reappear when a placebo was given?                            | −1  | 1  | 0           |
| g Was the drug detected in the blood (or other fluids) in concentrations known to be toxic? | 1   | 0  | 0           |
| h Was the reaction more severe when the dose was increased or less severe when the dose was decreased? | 1   | 0  | 0           |
| i Did the patient have a similar reaction to the same or similar drugs in any previous exposure? | 1   | 0  | 0           |
| j Was the adverse event confirmed by any objective evidence?                     | 1   | 0  | 0           |
Declarations

Ethics approval and consent to participate
Not applicable.

Consent for publication
Written informed consent was obtained from the patients for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Competing interests
The authors declare that there are no competing interests regarding publication of this paper.

Author details
1 Shaoxing University School of Medicine, Shaoxing, China. 2 The First Affiliated Hospital of Shaoxing University (Shaoxing People's Hospital), Shaoxing, China.

Received: 26 April 2021   Accepted: 23 August 2022
Published online: 12 October 2022

References
1. Mir N, Chin SA, Riddell MC, Beaudry JL. Genomic and non-genomic actions of glucocorticoids on adipose tissue lipid metabolism. Int J Mol Sci. 2021;22(16):8503.
2. Meszaros K, Patocs A. Glucocorticoids influencing Wnt/β-catenin pathway, multiple sites, heterogeneous effects. Molecules. 2020;25(7):E1489.
3. Pan X, Xie F, Xiao D, Zhou X, Xiao J. Design, synthesis, and renal targeting of methylprednisolone-lysozyme. Int J Mol Sci. 2020;21(6):E1922.
4. Gagnier JJ, Kienle G, Altman DG, Moher D, Sox H, Riley D, et al. CARE guidelines: consensus-based clinical case reporting guideline development. J Med Case Rep. 2013;10(7):223.
5. Expert consensus on emergency application of corticosteroid. Chin J Emerg Med 2020; 29(06):765–772.
6. Alkhatib AA, Anglade P. Alirocumab-induced hyperlipasemia and hyperamylasemia. Ann Pharmacother. 2020;54(7):720–1.
7. Muniraj T, Dang S, Pritchumoni CS. Pancreatitis or not?: Elevated lipase and amylase in ICU patients. J Crit Care. 2015;30(6):1370–5.
8. Huang C, Bai L, Xue X, Peng L, Jiang J, Zhang X. Hyperamylasemia as an early predictor of mortality in patients with acute paraparat poisoning. J Int Med Res. 2020;48(3):30066520910037.
9. Vidal E, Alberici I, Verina E. Italian Registry of Pediatric Chronic Dialysis. Acute pancreatitis in children on chronic maintenance dialysis. Pediatr Nephrol. 2019;34(9):1501–12.
10. Divvedi P, Kumar RR, Dhokia A, Adarsh MB, Malhotra S, Kakkar N, et al. Corticosteroid-associated lupus pancreatitis: a case series and systematic review of the literature. Lupus. 2019;28(6):731–9.
11. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–45.
12. Logidion CD, Moessner J, Williams JA, Goldfine ID. Glucocorticoids increase amylase mRNA levels, secretory granules, and secretion in pancreatic acinar AM42J cells. J Cell Biol. 1985;100(4):1200–8.
13. Nango D, Nakashima H, Hirose Y, Shina M, Echizen H. Causal relationship between acute pancreatitis and methylprednisolone pulse therapy for fulminant autoimmune hepatitis: a case report and review of literature. J Pharm Health Care Sci. 2018;4:14.
14. Richard K, Waggoner G, Donnan M, Ayers K, Madruga M, Carlan SJ. Epidural steroid injection-induced pancreatitis: a case report. Am J Case Rep. 2020;10(2021):e921241.
15. Chinese Pancreatic Surgery Association, Chinese Society of Surgery, Chinese Medical Association. [Guidelines for diagnosis and treatment of acute pancreatitis in China (2021)]. Zhonghua Wai Ke Za Zhi. 2021;59(7):578–87

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.